Wearable Sensors and Video-Based Testing to Track Arm Function After Treatment for Neurogenic Thoracic Outlet Syndrome

November 13, 2026 updated by: Bryan M. Burt, MD, FACS, University of California, Los Angeles

Remote Assessment and Digital Biomarker-Based Testing for Neurogenic Thoracic Outlet Syndrome: Longitudinal Follow-up After Physical Therapy or Surgery (Study 2)

The goal of this study is to learn whether wearable motion sensors and video-based movement analysis can track changes in arm function over time in adults with neurogenic thoracic outlet syndrome (NTOS) who are receiving standard treatment (physical therapy or surgery).

NTOS happens when nerves between the neck and shoulder are squeezed, causing pain, numbness, weakness, and trouble using the arm. There is currently no objective test to measure how severe NTOS is or how well treatment is working.

The main questions this study aims to answer are:

  • Can digital measurements of arm movement, collected with wearable sensors and with standard webcam video, detect changes in arm function after NTOS treatment?
  • Are these digital measurements more sensitive to change than standard questionnaires?
  • Do video-based measurements agree with sensor-based measurements?
  • Can measurements taken before treatment help predict who will improve with physical therapy?

This study does not assign or change treatment. Physical therapy or surgery is chosen by each participant's doctors as part of usual care.

Participants will:

  • Complete 5 study visits over about 12 months: before treatment and 1 and 2 months after treatment (in clinic), and 6 and 12 months after treatment (remote telemedicine visits)
  • At each visit, perform a short arm movement task (the "Press Test," a 20-second hand-over-head exercise) while wearing motion sensors and/or being recorded on video
  • Complete questionnaires about arm function, pain, mood, and overall health

Study Overview

Detailed Description

Neurogenic thoracic outlet syndrome (NTOS) is a disorder of dynamic compression of the brachial plexus between the first rib and the scalene muscles. Diagnosis currently relies on subjective clinical assessment, and there are no objective measures to monitor response to treatment. This study evaluates a remote patient monitoring platform that extracts digital biomarkers of upper extremity motor function from the Press Test, a 20-second repetitive hand-over-head task designed to provoke NTOS symptoms.

This is a single-site, prospective longitudinal study at the UCLA Thoracic Outlet Syndrome Center. Adults with a treating-physician diagnosis of NTOS who are proceeding with standard-of-care treatment (physical therapy and/or surgery) are followed for 12 months. Treatment selection is made by the treating clinicians and is not assigned by the study. Approximately 50 participants undergoing physical therapy and 50 undergoing surgery will be enrolled.

At each of five time points (baseline 0-1 month before treatment; 1, 2, 6, and 12 months after treatment), participants perform the Press Test while digital biomarkers are captured with wearable inertial sensors and with AI-based analysis of standard webcam video. The baseline, 1-month, and 2-month assessments are performed in person; the 6- and 12-month assessments are performed remotely via secure telehealth, with sensors provided in clinic or mailed to the participant with written instructions and staff support. Patient-reported outcomes (DASH, VAS pain, Zung Self-Rating Depression Scale, and PROMIS Global Health) are collected at each time point. Feasibility and acceptability of remote assessment are evaluated through visit completion rates, time burden, technical issues, and a technology acceptance questionnaire.

Analyses will use linear and generalized linear mixed models to assess change over time, intraclass correlation coefficients and Bland-Altman analyses to compare sensor- and video-derived measures, and exploratory models to identify baseline predictors of response to physical therapy.

This study is funded by the National Institutes of Health (R01HD121303).

Study Type

Observational

Enrollment (Estimated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults aged 18 to 60 years with a treating-physician diagnosis of neurogenic thoracic outlet syndrome who are evaluated at the UCLA Thoracic Outlet Syndrome Center and are proceeding with standard-of-care physical therapy or surgery.

Description

Inclusion Criteria:

  • Men or women aged 18 to 60 years
  • Treating-physician diagnosis of neurogenic thoracic outlet syndrome (NTOS)
  • Plan for standard-of-care treatment (physical therapy and/or surgery) at UCLA
  • Right-handed, left-handed, or ambidextrous
  • Able to provide informed consent and complete study activities

Exclusion Criteria:

  • Bilateral NTOS
  • Previous surgery for NTOS at any time, or NTOS-directed physical therapy within the past 2 months
  • Venous thoracic outlet syndrome
  • Arterial thoracic outlet syndrome
  • NTOS together with another condition affecting the upper extremity
  • Cognitive impairment
  • Acute or chronic conditions unrelated to NTOS that may affect upper extremity function (e.g., stroke, Parkinson's disease, arthritis, cancer)
  • History of drug or alcohol abuse within the past 6 months
  • Inability to participate in follow-up assessments (e.g., plans to move out of state within 12 months, or inability to complete remote follow-up visits)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Physical Therapy

Adults with neurogenic thoracic outlet syndrome whose treating physician has recommended standard-of-care physical therapy. Participants complete digital biomarker assessments (Press Test with wearable sensors and webcam video) and patient-reported outcome questionnaires before treatment and at 1, 2, 6, and 12 months after treatment. Treatment is not assigned by the study.

Surgery

Adults with neurogenic thoracic outlet syndrome whose treating physician has recommended standard-of-care surgical decompression (e.g., first rib resection, scalenectomy, and brachial plexus neurolysis). Participants complete digital biomarker assessments (Press Test with wearable sensors and webcam video) and patient-reported outcome questionnaires before treatment and at 1, 2, 6, and 12 months after treatment. Treatment is not assigned by the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Press Test Digital Biomarkers of Upper Extremity Function
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Digital biomarkers of upper extremity motor function (representing slowness, weakness, rigidity, exhaustion, and unsteadiness, e.g., speed, power, rise time, and range of motion) extracted from a 20-second repetitive hand-over-head Press Test using wearable inertial sensors and AI-based webcam video analysis. Change from baseline will be assessed at each follow-up time point.

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment
Change in Disabilities of the Arm, Shoulder and Hand (DASH) Score
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

The DASH is a 30-item self-reported questionnaire of upper extremity disability and symptoms. Scores range from 0 to 100; higher scores indicate greater disability.

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Pain Intensity (Visual Analog Scale)
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Self-reported pain intensity on a 0 to 10 visual analog scale; higher scores indicate worse pain.

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment
Change in Zung Self-Rating Depression Scale (SDS) Score
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

20-item self-reported depression scale. Raw scores range from 20 to 80; higher scores indicate more severe depressive symptoms.

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment
Change in PROMIS Global Health Physical and Mental Health T-Scores
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

PROMIS Global Health v1.2 (10 items) yields Global Physical Health and Global Mental Health T-scores (population mean 50, SD 10); higher scores indicate better health.

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment
Agreement Between Sensor-Based and Video-Based Digital Biomarkers
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Agreement between digital biomarkers derived from wearable sensors and from AI-based webcam video analysis during the Press Test, assessed by intraclass correlation coefficient (ICC) at each time point.

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment
Baseline Digital Biomarkers as Predictors of Response to Physical Therapy
Time Frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Performance of machine learning models using pre-treatment digital biomarkers, demographics, and clinical factors to predict non-response to physical therapy (no meaningful symptom improvement), reported as area under the ROC curve (AUC).

Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 20, 2026

Primary Completion (Estimated)

November 1, 2030

Study Completion (Estimated)

November 1, 2031

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB-26-0380-Study2
  • R01HD121303 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe